Dainippon pharm proceeding with clinical development in west for licensing out

摘要

Dainippon Pharmaceutical is proceeding with the clinical development of two drug candidates in the west, aiming to license them out after they have cleared phase-II tests. "AS-3201", for treating diabetic complications, has recently been put into phase-II clinical tests in both the U.S. and Canada, "AC-3933", an antidementia agent, is expected to enter the phase-II stage in Europe next year.